BenevolentAI
London
About BenevolentAI
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $292.0M
- Funding stage: IPO
- Last round: Private Equity (Sep 2019)
- Ticker: ams:BAI
- Website: benevolent.com
- Phone: +44 2037 819 360
Industries & Categories
Artificial Intelligence (AI), Big Data, Biotechnology, Machine Learning, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/benevolentai-101512 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.